http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-000628-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate | 1996-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c74475b2d6120967225e65c554a201f4 |
| publicationDate | 1999-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-000628-B1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITIONS, CONTAINING INHIBITORS INHIBITION AGGREGATION |
| abstract | 1. A pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula and the pharmaceutically acceptable salts thereof, wherein R<4>is aryl, C1-10 alkyl or C1-10 arylalkyl R<5> is wherein R<8> is hydroxy or C1-10 alkyloxy; p is zero or one; and m is an integer from two to six; and pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pharmaceutically acceptable pH; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient. 2. A pharmaceutical composition of Claim 1 comprising a) a pharmaceutically effective amount of a compound having the formula and the pharmaceutically acceptable salts thereof, wherein R<4>is aryl, C1-10 alkyl or C1-10 arylalkyl, R<5> is wherein R<8> is hydroxy or C1-10 alkyloxy; p is zero or one; and m is an integer from two to six; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) between about 50-500 milliosmoles of a tonicity adjusting agent. 3. A composition of Claim 2 comprising about 0.01 -0.5 mg/ml of a compound having the formula and the pharmaceutically acceptable salts thereof, wherein R<4>is aryl, C1-10 alkyl or C1-10 arylalkyl R<5> is wherein R<8> is hydroxy or C1-10 alkyloxy; p is zero or one; and m is an integer from two to six; about 2-100 mM citrate buffer, between about 50-500 milliosmoles tonicity adjusting agent, and water. 4. A composition of Claim 3 comprising about 0.01-0.5 mg/ml of a compound having the formula and the pharmaceutically acceptable salts thereof, wherein R<4> is aryl, C1-10 alkyl or C1-10 arylalkyl, R<5> is wherein R<8> is hydroxy or C1-10 alkyloxy; p is zero or one; and m is an integer from two to six; about 2-20 mM citrate buffer, about 290 milliosmoles tonicity adjusting agent, and water. 5. A pharmaceutical composition of Claim 4, wherein the compound is 2-S-(n-butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic acid. 6. A pharmaceutical composition of Claim 5, wherein the amount of 2-S-(n-butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic acid is about 0.05 to about 0.25 mg/ml, and the amount of citrate buffer is about 2-20 mM. 7. A pharmaceutical composition of Claim 6, wherein the amount of 2-S-(n-butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic acid is about 0.25 mg/ml, the amount of citrate buffer is about 10 mM, the amount oftonicity adjusting agent is about 290 milliosmoles, and the pH is about 6. 8. A method for inhibiting the aggregation of blood platelets in a mammal, comprising intravenously treating the mammal with a pharmaceutically effective amount of the composition of Claim 1. 9. A method of Claim 8 where the mammal is a human. 10. A method for inhibiting the aggregation of blood platelets in a mammal, comprising intravenously treating the mammal with a pharmaceutically effective amount of the composition of Claim 7. 11. A method of Claim 10 where the mammal is a human. |
| priorityDate | 1995-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.